Plasmodium falciparum infection prevalence among children aged 6-59 months from independent DHS and HIV surveys: Nigeria, 2018.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
03 02 2023
Historique:
received: 24 08 2022
accepted: 16 01 2023
entrez: 3 2 2023
pubmed: 4 2 2023
medline: 8 2 2023
Statut: epublish

Résumé

Prevalence estimates are critical for malaria programming efforts but generating these from non-malaria surveys is not standard practice. Malaria prevalence estimates for 6-59-month-old Nigerian children were compared between two national household surveys performed simultaneously in 2018: a Demographic and Health Survey (DHS) and the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). DHS tested via microscopy (n = 8298) and HRP2-based rapid diagnostic test (RDT, n = 11,351), and NAIIS collected dried blood spots (DBS) which were later tested for histidine-rich protein 2 (HRP2) antigen (n = 8029). National Plasmodium falciparum prevalence was 22.6% (95% CI 21.2- 24.1%) via microscopy and 36.2% (34.6- 37.8%) via RDT according to DHS, and HRP2 antigenemia was 38.3% (36.7-39.9%) by NAIIS DBS. Between the two surveys, significant rank-order correlation occurred for state-level malaria prevalence for RDT (Rho = 0.80, p < 0.001) and microscopy (Rho = 0.75, p < 0.001) versus HRP2. RDT versus HRP2 positivity showed 24 states (64.9%) with overlapping 95% confidence intervals from the two independent surveys. P. falciparum prevalence estimates among 6-59-month-olds in Nigeria were highly concordant from two simultaneous, independently conducted household surveys, regardless of malaria test utilized. This provides evidence for the value of post-hoc laboratory HRP2 detection to leverage non-malaria surveys with similar sampling designs to obtain accurate P. falciparum estimates.

Identifiants

pubmed: 36737630
doi: 10.1038/s41598-023-28257-0
pii: 10.1038/s41598-023-28257-0
pmc: PMC9898257
doi:

Substances chimiques

Antigens, Protozoan 0
Proteins 0
Protozoan Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1998

Informations de copyright

© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

PLoS One. 2014 Apr 01;9(4):e93684
pubmed: 24691467
Am J Trop Med Hyg. 2018 May;98(5):1389-1396
pubmed: 29557342
Clin Lab Med. 2013 Sep;33(3):461-503
pubmed: 23931835
Malar J. 2018 Sep 17;17(1):333
pubmed: 30223852
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD008122
pubmed: 21735422
J Infect Dis. 2018 Feb 14;217(5):685-692
pubmed: 29220497
BMC Med. 2017 Jun 30;15(1):121
pubmed: 28662646
Malar J. 2017 Nov 7;16(1):451
pubmed: 29115966
Clin Infect Dis. 2016 Dec 15;63(suppl 5):S290-S297
pubmed: 27941107
Malar J. 2019 Feb 21;18(1):46
pubmed: 30791912
J Clin Microbiol. 2019 Feb 27;57(3):
pubmed: 30626660
BMC Infect Dis. 2018 Aug 22;18(1):413
pubmed: 30134861
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):119-27
pubmed: 18165483
Malar J. 2017 Mar 24;16(1):128
pubmed: 28340585
PLoS One. 2017 Feb 13;12(2):e0172139
pubmed: 28192523
Malar J. 2019 Mar 12;18(1):73
pubmed: 30866947
Malar J. 2018 Dec 5;17(1):452
pubmed: 30518365
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30404944
Malar J. 2015 Oct 26;14:418
pubmed: 26502920
J Infect Dis. 2019 Jan 9;219(3):437-447
pubmed: 30202972
Parasit Vectors. 2015 Feb 22;8:118
pubmed: 25888970
Malar J. 2019 Nov 26;18(1):375
pubmed: 31771572
Malar J. 2015 Nov 04;14:436
pubmed: 26537125

Auteurs

Adan Oviedo (A)

Malaria Branch, Division of Parasitic Diseases and Malaria, United States Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.

Ado Abubakar (A)

Institute of Human Virology Nigeria, Abuja, Nigeria.

Perpetua Uhomoibhi (P)

National Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria.

Mark Maire (M)

US President's Malaria Initiative, Abuja, Nigeria.

Uwem Inyang (U)

United States Agency for International Development, Abuja, Nigeria.

Bala Audu (B)

National Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria.

Nnaemeka C Iriemenam (NC)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.

Abiodun Ogunniyi (A)

Nigeria Centre for Disease Control, Abuja, Nigeria.

James Ssekitooleko (J)

The Global Fund to Fight AIDS, Tuberculosis, and Malaria, Geneva, Switzerland.

Jo-Angeline Kalambo (JA)

The Global Fund to Fight AIDS, Tuberculosis, and Malaria, Geneva, Switzerland.

Stacie M Greby (SM)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.

Nwando Mba (N)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Mahesh Swaminathan (M)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.

Chikwe Ihekweazu (C)

Nigeria Centre for Disease Control, Abuja, Nigeria.

McPaul I Okoye (MI)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Abuja, FCT, Nigeria.

Eric Rogier (E)

Malaria Branch, Division of Parasitic Diseases and Malaria, United States Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA.

Laura C Steinhardt (LC)

Malaria Branch, Division of Parasitic Diseases and Malaria, United States Centers for Disease Control and Prevention, Atlanta, GA, 30029, USA. iyp6@cdc.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH